Immediate Impact
66 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
Works of Solenn Brosseau being referenced
Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
2022
Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Solenn Brosseau | 399 | 425 | 137 | 51 | 688 | |
| Hidenori Mizugaki | 228 | 393 | 201 | 39 | 695 | |
| Pietro De Placido | 376 | 461 | 229 | 49 | 764 | |
| Malaka Ameratunga | 276 | 364 | 260 | 44 | 801 | |
| Masato Sugano | 223 | 412 | 176 | 44 | 677 | |
| Ana B. Enguita | 400 | 305 | 144 | 39 | 650 | |
| Dengfeng Ren | 332 | 500 | 175 | 43 | 773 | |
| Paola Marroni | 275 | 250 | 171 | 39 | 661 | |
| Kyung Han Nam | 338 | 415 | 219 | 45 | 799 | |
| Hanna Koseła-Paterczyk | 415 | 407 | 209 | 71 | 739 | |
| Jian Zhang | 225 | 366 | 226 | 57 | 684 |
All Works
Login with ORCID to disown or claim papers
Loading papers...